Increased anxiety in corticotropin-releasing factor type 2 receptor-null mice requires recent acute stress exposure and is associated with dysregulated serotonergic activity in limbic brain areas

Biology of Mood & Anxiety Disorders

Orna Issler⁴  Roderick N Carter³  Evan D Paul²  Paul AT Kelly¹  Henry J Olverman¹  Adi Neufeld-Cohen⁴  Yael Kuperman⁴  Christopher A Lowry²  Jonathan R Seckl³  Alon Chen⁴  Pauline M Jamieson³ 

[1] Centre for Cognitive and Neural Systems, University of Edinburgh, 1 George Square, Edinburgh EH8 9JZ, UK

[2] Department of Integrative Physiology and Center for Neuroscience, University of Colorado Boulder, Boulder, CO 80309, USA

[3] Centre for Cardiovascular Science, Queens Medical Research Institute, 47 Little France Crescent, Edinburgh EH16 4TJ, UK

[4] Department of Neurobiology, Weizmann Institute of Science, Rehovot 76100, Israel

关键词: Stress;    Serotonin;    Raphe nuclei;    Corticotropin-releasing factor type 2 receptor;    Anxiety;    5-HT_1A receptor;   

Others  :  791754
DOI  :  10.1186/2045-5380-4-1

 received in 2013-07-26, accepted in 2013-12-11,  发布年份 2014

【 摘 要 】

Background

Corticotropin-releasing factor type 2 receptors (CRFR2) are suggested to facilitate successful recovery from stress to maintain mental health. They are abundant in the midbrain raphe nuclei, where they regulate serotonergic neuronal activity and have been demonstrated to mediate behavioural consequences of stress. Here, we describe behavioural and serotonergic responses consistent with maladaptive recovery from stressful challenge in CRFR2-null mice.

Results

CRFR2-null mice showed similar anxiety levels to control mice before and immediately after acute restraint stress, and also after cessation of chronic stress. However, they showed increased anxiety by 24 hours after restraint, whether or not they had been chronically stressed.

Serotonin (5-HT) and 5-hydroxyindoleacetic acid (5-HIAA) contents were quantified and the level of 5-HIAA in the caudal dorsal raphe nucleus (DRN) was increased under basal conditions in CRFR2-null mice, indicating increased 5-HT turnover. Twenty-four hours following restraint, 5-HIAA was decreased only in CRFR2-null mice, suggesting that they had not fully recovered from the challenge. In efferent limbic structures, CRFR2-null mice showed lower levels of basal 5-HT in the lateral septum and subiculum, and again showed a differential response to restraint stress from controls.

Local cerebral glucose utilization (LCMRglu) revealed decreased neuronal activity in the DRN of CRFR2-null mice under basal conditions. Following 5-HT receptor agonist challenge, LCMRglu responses indicated that 5-HT_1A receptor responses in the DRN were attenuated in CRFR2-null mice. However, postsynaptic 5-HT receptor responses in forebrain regions were intact.

Conclusions

These results suggest that CRFR2 are required for proper functionality of 5-HT_1A receptors in the raphe nuclei, and are key to successful recovery from stress. This disrupted serotonergic function in CRFR2-null mice likely contributes to their stress-sensitive phenotype. The 5-HT content in lateral septum and subiculum was notably altered. These areas are important for anxiety, and are also implicated in reward and the pathophysiology of addiction. The role of CRFR2 in stress-related psychopathologies deserves further consideration.

【 授权许可】

   
2014 Issler et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 1.

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

【 参考文献 】

• [1]Reid S, Barbui C: Long term treatment of depression with selective serotonin reuptake inhibitors and newer antidepressants. BMJ 2010, 340:c1468.
• [2]Bandelow B, Zohar J, Hollander E, Kasper S, Möller HJ, Zohar J, Hollander E, Kasper S, Möller HJ, Bandelow B, Allgulander C, Ayuso-Gutierrez J, Baldwin DS, Buenvicius R, Cassano G, Fineberg N, Gabriels L, Hindmarch I, Kaiya H, Klein DF, Lader M, Lecrubier Y, Lépine JP, Liebowitz MR, Lopez-Ibor JJ, Marazziti D, Miguel EC, Oh KS, Preter M, WFSBP Task Force on Treatment Guidelines for Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders, et al.: World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision. World J Biol Psychiatry 2008, 9:248-312.
• [3]Steinbusch HW: Distribution of serotonin-immunoreactivity in the central nervous system of the rat-cell bodies and terminals. Neuroscience 1981, 6:557-618.
• [4]Steinbusch HW, Verhofstad AA, Joosten HW: Localization of serotonin in the central nervous system by immunohistochemistry: description of a specific and sensitive technique and some applications. Neuroscience 1978, 3:811-819.
• [5]Vale W, Spiess J, Rivier C, Rivier J: Characterization of a 41 residue ovine hypothalamic peptide that stimulates the secretion of corticotropin and β-endorphin. Science 1981, 213:1394-1397.
• [6]Müller MB, Zimmermann S, Sillaber I, Hagemeyer TP, Deussing JM, Timpl P, Kormann MS, Droste SK, Kühn R, Reul JM, Holsboer F, Wurst W: Limbic corticotropin-releasing hormone receptor 1 mediates anxiety-related behavior and hormonal adaptation to stress. Nat Neurosci 2003, 6:1100-1107.
• [7]Vale W, Rivier C, Brown MR, Spiess J, Koob G, Swanson L, Bilezikjian L, Bloom F, Rivier J: Chemical and biological characterization of corticotropin releasing factor. Recent Prog Horm Res 1983, 39:245-270.
• [8]Lloyd RB, Nemeroff CB: The role of corticotropin-releasing hormone in the pathophysiology of depression: therapeutic implications. Curr Top Med Chem 2011, 11:609-617.
• [9]Sanchez MM, Young LJ, Plotsky PM, Insel TR: Autoradiographic and in situ hybridization localization of corticotropin-releasing factor 1 and 2 receptors in nonhuman primate brain. J Comp Neurol 1999, 408:365-377.
• [10]Chalmers DT, Lovenberg TW, De Souza EB: Localization of novel corticotropin-releasing factor receptor (CRF2) mRNA expression to specific subcortical nuclei in rat brain: comparison with CRF1 receptor mRNA expression. J Neurosci 1995, 15:6340-6350.
• [11]Van Pett K, Viau V, Bittencourt JC, Chan RKW, Li H-Y, Arias C, Prins GS, Perrin M, Vale W, Sawchenko PE: Distribution of mRNAs encoding CRF receptors in brain and pituitary of rat and mouse. J Comp Neurol 2000, 428:191-212.
• [12]Lukkes JL, Staub DR, Dietrich A, Truitt W, Neufeld-Cohen A, Chen A, Johnson PL, Shekhar A, Lowry CA: Topographical distribution of corticotropin-releasing factor type 2 receptor-like immunoreactivity in the rat dorsal raphe nucleus: co-localization with tryptophan hydroxylase. Neuroscience 2011, 183:47-63.
• [13]Day HE, Greenwood BN, Hammack SE, Watkins LR, Fleshner M, Maier SF, Campeau S: Differential expression of 5HT-1A, α1b adrenergic, CRF-R1, and CRF-R2 receptor mRNA in serotonergic, γ-aminobutyric acidergic, and catecholaminergic cells of the rat dorsal raphe nucleus. J Comp Neurol 2004, 474:364-378.
• [14]Lowry CA, Rodda JE, Lightman SL, Ingram CD: Corticotropin-releasing factor increases in vitro firing rates of serotonergic neurons in the rat dorsal raphe nucleus: evidence for activation of a topographically organized mesolimbocortical serotonergic system. J Neurosci 2000, 20:7728-7736.
• [15]Kirby LG, Rice KC, Valentino RJ: Effects of corticotropin-releasing factor on neuronal activity in the serotonergic dorsal raphe nucleus. Neuropsychopharmacology 2000, 22:148-162.
• [16]Waselus M, Nazzaro C, Valentino RJ, Van Bockstaele EJ: Stress-induced redistribution of corticotropin-releasing factor receptor subtypes in the dorsal raphe nucleus. Biol Psychiatry 2009, 66:76-83.
• [17]Lukkes J, Vuong S, Scholl J, Oliver H, Forster G: Corticotropin-releasing factor receptor antagonism within the dorsal raphe nucleus reduces social anxiety-like behavior after early-life social isolation. J Neurosci 2009, 29:9955-9960.
• [18]Valentino RJ, Lucki I, Van Bockstaele E: Corticotropin-releasing factor in the dorsal raphe nucleus: linking stress coping and addiction. Brain Res 2010, 1314:29-37.
• [19]Clark MS, McDevitt RA, Hoplight BJ, Neumaier JF: Chronic low dose ovine corticotropin releasing factor or urocortin II into the rostral dorsal raphe alters exploratory behavior and serotonergic gene expression in specific subregions of the dorsal raphe. Neuroscience 2007, 146:1888-1905.
• [20]Linthorst ACE: Stress, corticotropin-releasing factor and serotonergic neurotransmission. In Handbook of Stress and the Brain. Volume 1. 1st edition. Edited by Steckler T, Kalin NH, Reul JMHM. Amsterdam: Elsevier; 2005:503-524.
• [21]Lovenberg TW, Liaw CW, Grigoriadis DE, Clevenger W, Chalmers DT, De Souza EB, Oltersdorf T: Cloning and characterization of a functionally distinct corticotropin-releasing factor receptor subtype from rat brain. Proc Natl Acad Sci U S A 1995, 92:836-840.
• [22]Perrin MH, Donaldson C, Chen R, Blount A, Berggren T, Bilezikjian L, Sawchenko P, Vale WW: Identification of a second corticotropin-releasing factor receptor gene and characterization of a cDNA expressed in heart. Proc Natl Acad Sci U S A 1995, 92:2969-2973.
• [23]Chen R, Lewis KA, Perrin MH, Vale WW: Expression cloning of a human corticotropin releasing factor (CRF) receptor. Proc Natl Acad Sci USA 1993, 90:8967-8971.
• [24]Fekete EM, Zorrilla EP: Physiology, pharmacology, and therapeutic relevance of urocortins in mammals: ancient CRF paralogs. Front Neuroendocrinol 2007, 28:1-27.
• [25]Lewis K, Li C, Perrin MH, Blount A, Kunitake K, Donaldson C, Vaughan J, Reyes TM, Gulyas J, Fischer W, Bilezikjian L, Rivier J, Sawchenko PE, Vale WW: Identification of Urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc Natl Acad Sci U S A 2001, 98:7570-7575.
• [26]Reyes TM, Lewis K, Perrin MH, Kunitake KS, Vaughan J, Arias CA, Hogenesch JB, Gulyas J, Rivier J, Vale WW, Sawchenko PE: Urocortin II: a member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. Proc Natl Acad Sci USA 2001, 98:2843-2848.
• [27]Vaughan JM, Donaldson C, Bittencourt J, Perrin MH, Lewis K, Sutton S, Chan R, Turnbull A, Lovejoy D, Rivier C, Sawchenko PE, Vale W: Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature 1995, 378:287-292.
• [28]Hsu SY, Hsueh AJ: Human stresscopin and stresscopin-related peptide are selective ligands for the type 2 corticotropin-releasing hormone receptor. Nat Med 2001, 7:605-611.
• [29]Bittencourt JC, Vaughan J, Arias C, Rissman RA, Vale WW, Sawchenko PE: Urocortin expression in rat brain: evidence against a pervasive relationship of urocortin-containing projections with targets bearing type 2 CRF receptors. J Comp Neurol 1999, 415:285-312.
• [30]Kozicz T, Yanaihara H, Arimura A: Distribution of urocortin-like immunoreactivity in the central nervous system of the rat. J Comp Neurol 1998, 391:1-10.
• [31]Weitemier AZ, Ryabinin AE: Lesions of the Edinger-Westphal nucleus alter food and water consumption. Behav Neurosci 2005, 119:1235-1243.
• [32]Pernar L, Curtis AL, Vale WW, Rivier JE, Valentino RJ: Selective activation of corticotropin-releasing factor-2 receptors on neurochemically identified neurons in the rat dorsal raphe nucleus reveals dual actions. J Neurosci 2004, 24:1305-1311.
• [33]Staub DR, Evans AK, Lowry CA: Evidence supporting a role for corticotropin-releasing factor type 2 (CRF2) receptors in the regulation of subpopulations of serotonergic neurons. Brain Res 2006, 1070:77-89.
• [34]Amat J, Tamblyn JP, Paul ED, Bland ST, Amat P, Foster AC, Watkins LR, Maier SF: Microinjection of urocortin 2 into the dorsal raphe nucleus activates serotonergic neurons and increases extracellular serotonin in the basolateral amygdala. Neuroscience 2004, 129:509-519.
• [35]Forster GL, Pringle RB, Mouw NJ, Vuong SM, Watt MJ, Burke AR, Lowry CA, Summers CH, Renner KJ: Corticotropin-releasing factor in the dorsal raphe nucleus increases medial prefrontal cortical serotonin via type 2 receptors and median raphe nucleus activity. Eur J Neurosci 2008, 28:299-310.
• [36]Lukkes JL, Forster GL, Renner KJ, Summers CH: Corticotropin-releasing factor 1 and 2 receptors in the dorsal raphe differentially affect serotonin release in the nucleus accumbens. Eur J Pharmacol 2008, 578:185-193.
• [37]Hammack SE, Pepin JL, DesMarteau JS, Watkins LR, Maier SF: Low doses of corticotropin-releasing hormone injected into the dorsal raphe nucleus block the behavioral consequences of uncontrollable stress. Behav Brain Res 2003, 147:55-64.
• [38]Hammack SE, Schmid MJ, LoPresti ML, Der-Avakian A, Pellymounter MA, Foster AC, Watkins LR, Maier SF: Corticotropin releasing hormone type 2 receptors in the dorsal raphe nucleus mediate the behavioral consequences of uncontrollable stress. J Neurosci 2003, 23:1019-1025.
• [39]Neufeld-Cohen A, Kelly PA, Paul ED, Carter RN, Skinner E, Olverman HJ, Vaughan JM, Issler O, Kuperman Y, Lowry CA, Vale WW, Seckl JR, Chen A, Jamieson PM: Chronic activation of corticotropin-releasing factor type 2 receptors reveals a key role for 5-HT1A receptor responsiveness in mediating behavioral and serotonergic responses to stressful challenge. Biol Psychiatry 2012, 72:437-447.
• [40]Neufeld-Cohen A, Evans AK, Getselter D, Spyroglou A, Hill A, Gil S, Tsoory M, Beuschlein F, Lowry CA, Vale W, Chen A: Urocortin-1 and -2 double-deficient mice show robust anxiolytic phenotype and modified serotonergic activity in anxiety circuits. Mol Psychiatry 2010, 15:426-441. 339
• [41]Neufeld-Cohen A, Tsoory MM, Evans AK, Getselter D, Gil S, Lowry CA, Vale WW, Chen A: A triple urocortin knockout mouse model reveals an essential role for urocortins in stress recovery. Proc Natl Acad Sci USA 2010, 107:19020-19025.
• [42]Akimova E, Lanzenberger R, Kasper S: The serotonin-1A receptor in anxiety disorders. Biol Psychiatry 2009, 66:627-635.
• [43]Price ML, Curtis AL, Kirby LG, Valentino RJ, Lucki I: Effects of corticotropin-releasing factor on brain serotonergic activity. Neuropsychopharmacology 1998, 18:492-502.
• [44]Waselus M, Valentino RJ, Van Bockstaele EJ: Collateralized dorsal raphe nucleus projections: a mechanism for the integration of diverse functions during stress. J Chem Neuroanat 2011, 41:266-280.
• [45]Gray TS: Amygdaloid CRF pathways. Role in autonomic, neuroendocrine, and behavioral responses to stress. Ann NY Acad Sci 1993, 697:53-60.
• [46]Lazosky AJ, Britton DR: Effects of 5-HT-1A receptor agonists on CRF-induced behavior. Psychopharmacology (Berl) 1991, 104:132-136.
• [47]Todorovic C, Radulovic J, Jahn O, Radulovic M, Sherrin T, Hippel C, Spiess J: Differential activation of CRF receptor subtypes removes stress-induced memory deficit and anxiety. Eur J Neurosci 2007, 25:3385-3397.
• [48]Bakshi VP, Smith-Roe S, Newman SM, Grigoriadis DE, Kalin NH: Reduction of stress-induced behavior by antagonism of corticotropin-releasing hormone 2 (CRH2) receptors in lateral septum or CRH1 receptors in amygdala. J Neurosci 2002, 22:2926-2935.
• [49]Kuperman Y, Issler O, Regev L, Musseri I, Navon I, Neufeld-Cohen A, Gil S, Chen A: Perifornical urocortin-3 mediates the link between stress-induced anxiety and energy homeostasis. Proc Natl Acad Sci USA 2010, 107:8393-8398.
• [50]Bale TL, Contarino A, Smith GW, Chan R, Gold LH, Sawchenko PE, Koob GF, Vale WW, Lee K-F: Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress. Nat Gen 2000, 24:410-414.
• [51]Kishimoto T, Radulovic J, Radulovic M, Lin CR, Schrick C, Hooshmand F, Hermanson O, Rosenfeld MG, Spiess J: Deletion of Crhr2 reveals an anxiolytic role for corticotropin-releasing hormone receptor-2. Nat Genet 2000, 24:415-419.
• [52]Ducottet C, Griebel G, Belzung C: Effects of the selective nonpeptide corticotropin-releasing factor receptor 1 antagonist antalarmin in the chronic mild stress model of depression in mice. Prog Neuropsychopharmacol Biol Psych 2003, 27:625-631.
• [53]Dawson N, Ferrington L, Olverman HJ, Kelly PA: Novel analysis for improved validity in semi-quantitative 2-deoxyglucose autoradiographic imaging. J Neurosci Methods 2008, 175:25-35.
• [54]Dawson N, Ferrington L, Lesch KP, Kelly PA: Cerebral metabolic responses to 5-HT2A/C receptor activation in mice with genetically modified serotonin transporter (SERT) expression. Eur Neuropsychopharmacol 2011, 21:117-128.
• [55]Dawson N, Ferrington L, Olverman HJ, Harmar AJ, Kelly PA: Sex influences the effect of a lifelong increase in serotonin transporter function on cerebral metabolism. J Neurosci Res 2009, 87:2375-2385.
• [56]Paxinos G, Franklin KBJ: The Mouse Brain in Stereotaxic Coordinates. 2nd edition. San Diego: Academic Press; 2001.
• [57]Evans AK, Reinders N, Ashford KA, Christie IN, Wakerley JB, Lowry CA: Evidence for serotonin synthesis-dependent regulation of in vitro neuronal firing rates in the midbrain raphe complex. Eur J Pharmacol 2008, 590:136-149.
• [58]Harris HJ, Kotelevtsev Y, Mullins JJ, Seckl JR, Holmes MC: Intracellular regeneration of glucocorticoids by 11β-hydroxysteroid dehydrogenase (11β-HSD)-1 plays a key role in regulation of the hypothalamic-pituitary-adrenal axis: analysis of 11β-HSD-1-deficient mice. Endocrinology 2001, 142:114-120.
• [59]Seckl JR, Dickson KL, Fink G: Central 5,7-dihydroxytryptamine lesions decrease hippocampal glucocorticoid and mineralocorticoid receptor messenger ribonucleic acid expression. J Neuroendocrinol 1990, 2:911-916.
• [60]Holmes MC, French KL, Seckl JR: Modulation of serotonin and corticosteroid receptor gene expression in the rat hippocampus with circadian rhythm and stress. Brain Res Mol Brain Res 1995, 28:186-192.
• [61]De Souza EB, Kuyatt BL: Autoradiographic localization of 3H-paroxetine-labeled serotonin uptake sites in rat brain. Synapse 1987, 1:488-496.
• [62]Coste SC, Kesterson RA, Heldwein KA, Stevens SL, Heard AD, Hollis JH, Murray SE, Hill JK, Pantely GA, Hohimer AR, Hatton DC, Phillips TJ, Finn DA, Low MJ, Rittenberg MB, Stenzel P, Stenzel-Poore MP: Abnormal adaptations to stress and impaired cardiovascular function in mice lacking corticotropin-releasing hormone receptor-2. Nat Genet 2000, 24:403-409.
• [63]Reul JM, Holsboer F: Corticotropin-releasing factor receptors 1 and 2 in anxiety and depression. Curr Opin Pharmacol 2002, 2:23-33.
• [64]McEuen JG, Semsar KA, Lim MA, Bale TL: Influence of sex and corticotropin-releasing factor pathways as determinants in serotonin sensitivity. Endocrinology 2009, 150:3709-3716.
• [65]Stamp JA, Semba K: Extent of colocalization of serotonin and GABA in the neurons of the rat raphe nuclei. Brain Res 1995, 677:39-49.
• [66]Sharp T, Boothman L, Raley J, Queree P: Important messages in the ‘post’: recent discoveries in 5-HT neurone feedback control. Trends Pharmacol Sci 2007, 28:629-636.
• [67]Boothman L, Raley J, Denk F, Hirani E, Sharp T: In vivo evidence that 5-HT(2C) receptors inhibit 5-HT neuronal activity via a GABAergic mechanism. Br J Pharmacol 2006, 149:861-869.
• [68]Boothman LJ, Sharp T: A role for midbrain raphe gamma aminobutyric acid neurons in 5-hydroxytryptamine feedback control. Neuroreport 2005, 16:891-896.
• [69]Celada P, Puig MV, Casanovas JM, Guillazo G, Artigas F: Control of dorsal raphe serotonergic neurons by the medial prefrontal cortex: involvement of serotonin-1A, GABA(A), and glutamate receptors. J Neurosci 2001, 21:9917-9929.
• [70]Rozeske RR, Evans AK, Frank MG, Watkins LR, Lowry CA, Maier SF: Uncontrollable, but not controllable, stress desensitizes 5-HT1A receptors in the dorsal raphe nucleus. J Neurosci 2011, 31:14107-14115.
• [71]Flugge G: Regulation of monoamine receptors in the brain: dynamic changes during stress. Int Rev Cytol 2000, 195:145-213.
• [72]McQuade R, Sharp T: Functional mapping of dorsal and median raphe 5-hydroxytryptamine pathways in forebrain of the rat using microdialysis. J Neurochem 1997, 69:791-796.
• [73]Vertes RP: A PHA-L analysis of ascending projections of the dorsal raphe nucleus in the rat. J Comp Neurol 1991, 313:643-668.
• [74]Laporte AM, Lima L, Gozlan H, Hamon M: Selective in vivo labelling of brain 5-HT1A receptors by [3H]WAY 100635 in the mouse. Eur J Pharmacol 1994, 271:505-514.
• [75]Verge D, Daval G, Marcinkiewicz M, Patey A, el Mestikawy S, Gozlan H, Hamon M: Quantitative autoradiography of multiple 5-HT1 receptor subtypes in the brain of control or 5,7-dihydroxytryptamine-treated rats. J Neurosci 1986, 6:3474-3482.
• [76]Lowry CA, Hale MW, Evans AK, Heerkens J, Staub DR, Gasser PJ, Shekhar A: Serotonergic systems, anxiety, and affective disorder: focus on the dorsomedial part of the dorsal raphe nucleus. Ann NY Acad Sci 2008, 1148:86-94.
• [77]Lowry CA, Johnson PL, Hay-Schmidt A, Mikkelsen J, Shekhar A: Modulation of anxiety circuits by serotonergic systems. Stress 2005, 8:233-246.
• [78]Abrams JK, Johnson PL, Hay-Schmidt A, Mikkelsen JD, Shekhar A, Lowry CA: Serotonergic systems associated with arousal and vigilance behaviors following administration of anxiogenic drugs. Neuroscience 2005, 133:983-997.
• [79]Staub DR, Spiga F, Lowry CA: Urocortin 2 increases c-Fos expression in topographically organized subpopulations of serotonergic neurons in the rat dorsal raphe nucleus. Brain Res 2005, 1044:176-189.
• [80]Evans AK, Heerkens JL, Lowry CA: Acoustic stimulation in vivo and corticotropin-releasing factor in vitro increase tryptophan hydroxylase activity in the rat caudal dorsal raphe nucleus. Neurosci Lett 2009, 455:36-41.
• [81]Gardner KL, Thrivikraman KV, Lightman SL, Plotsky PM, Lowry CA: Early life experience alters behavior during social defeat: focus on serotonergic systems. Neuroscience 2005, 136:181-191.
• [82]Spiacci A Jr, Coimbra NC, Zangrossi H Jr: Differential involvement of dorsal raphe subnuclei in the regulation of anxiety- and panic-related defensive behaviors. Neuroscience 2012, 227:350-360.
• [83]Meloni EG, Reedy CL, Cohen BM, Carlezon WA Jr: Activation of raphe efferents to the medial prefrontal cortex by corticotropin-releasing factor: correlation with anxiety-like behavior. Biol Psychiatry 2008, 63:832-839.
• [84]Cordero MI, Poirier GL, Marquez C, Veenit V, Fontana X, Salehi B, Ansermet F, Sandi C: Evidence for biological roots in the transgenerational transmission of intimate partner violence. Transl Psychiatry 2012, 2:e106.
• [85]Waselus M, Galvez JP, Valentino RJ, Van Bockstaele EJ: Differential projections of dorsal raphe nucleus neurons to the lateral septum and striatum. J Chem Neuroanat 2006, 31:233-242.
• [86]Kohler C, Chan-Palay V, Steinbusch H: The distribution and origin of serotonin-containing fibers in the septal area: a combined immunohistochemical and fluorescent retrograde tracing study in the rat. J Comp Neurol 1982, 209:91-111.
• [87]O’Mara S: Controlling hippocampal output: the central role of subiculum in hippocampal information processing. Behav Brain Res 2006, 174:304-312.
• [88]Walker DL, Toufexis DJ, Davis M: Role of the bed nucleus of the stria terminalis versus the amygdala in fear, stress, and anxiety. Eur J Pharmacol 2003, 463:199-216.
• [89]Peyron C, Petit JM, Rampon C, Jouvet M, Luppi PH: Forebrain afferents to the rat dorsal raphe nucleus demonstrated by retrograde and anterograde tracing methods. Neuroscience 1998, 82:443-468.
• [90]Sink KS, Walker DL, Freeman SM, Flandreau EI, Ressler KJ, Davis M: Effects of continuously enhanced corticotropin releasing factor expression within the bed nucleus of the stria terminalis on conditioned and unconditioned anxiety. Mol Psychiatry 2013, 18:308-319.
• [91]Forster GL, Feng N, Watt MJ, Korzan WJ, Mouw NJ, Summers CH, Renner KJ: Corticotropin-releasing factor in the dorsal raphe elicits temporally distinct serotonergic responses in the limbic system in relation to fear behavior. Neuroscience 2006, 141:1047-1055.
• [92]Paul ED, Lowry CA: Functional topography of serotonergic systems supports the Deakin/Graeff hypothesis of anxiety and affective disorders. J Psychopharmacol 2013, 27:1090-1106.
• [93]Racca S, Spaccamiglio A, Esculapio P, Abbadessa G, Cangemi L, DiCarlo F, Portaleone P: Effects of swim stress and α-MSH acute pre-treatment on brain 5-HT transporter and corticosterone receptor. Pharmacol Biochem Behav 2005, 81:894-900.
• [94]Zhang J, Fan Y, Li Y, Zhu H, Wang L, Zhu MY: Chronic social defeat up-regulates expression of the serotonin transporter in rat dorsal raphe nucleus and projection regions in a glucocorticoid-dependent manner. J Neurochem 2012, 123:1054-1068.
• [95]Gomez F, Lahmame A, de Kloet ER, Armario A: Hypothalamic-pituitary-adrenal response to chronic stress in five inbred rat strains: differential responses are mainly located at the adrenocortical level. Neuroendocrinology 1996, 63:327-337.
• [96]Neal CR Jr, VanderBeek BL, Vazquez DM, Watson SJ Jr: Dexamethasone exposure during the neonatal period alters ORL1 mRNA expression in the hypothalamic paraventricular nucleus and hippocampus of the adult rat. Brain Res Dev Brain Res 2003, 146:15-24.
• [97]Chen GL, Miller GM: Advances in tryptophan hydroxylase-2 gene expression regulation: new insights into serotonin-stress interaction and clinical implications. Am J Med Genet 2012, 159B:152-171.
• [98]Vertes RP, Fortin WJ, Crane AM: Projections of the median raphe nucleus in the rat. J Comp Neurol 1999, 407:555-582.
• [99]Brunson KL, Grigoriadis DE, Lorang MT, Baram TZ: Corticotropin-releasing hormone (CRH) downregulates the function of its receptor (CRF1) and induces CRF1 expression in hippocampal and cortical regions of the immature rat brain. Exp Neurol 2002, 176:75-86.
• [100]Chen A, Perrin M, Brar B, Li C, Jamieson P, Digruccio M, Lewis K, Vale W: Mouse corticotropin-releasing factor receptor type 2α gene: isolation, distribution, pharmacological characterization and regulation by stress and glucocorticoids. Mol Endocrinol 2005, 19:441-458.
• [101]Bravo JA, Dinan TG, Cryan JF: Alterations in the central CRF system of two different rat models of comorbid depression and functional gastrointestinal disorders. Int J Neuropsychopharmacol 2011, 14:666-683.
• [102]Eghbal-Ahmadi M, Hatalski CG, Avishai-Eliner S, Baram TZ: Corticotropin releasing factor receptor type II (CRF2) messenger ribonucleic acid levels in the hypothalamic ventromedial nucleus of the infant rat are reduced by maternal deprivation. Endocrinology 1997, 138:5048-5051.
• [103]Korosi A, Veening JG, Kozicz T, Henckens M, Dederen J, Groenink L, van der Gugten J, Olivier B, Roubos EW: Distribution and expression of CRF receptor 1 and 2 mRNAs in the CRF over-expressing mouse brain. Brain Res 2006, 1072:46-54.
• [104]Hashimoto K, Nishiyama M, Tanaka Y, Noguchi T, Asaba K, Hossein PN, Nishioka T, Makino S: Urocortins and corticotropin releasing factor type 2 receptors in the hypothalamus and the cardiovascular system. Peptides 2004, 25:1711-1721.
• [105]Lebow M, Neufeld-Cohen A, Kuperman Y, Tsoory M, Gil S, Chen A: Susceptibility to PTSD-like behavior is mediated by corticotropin-releasing factor receptor type 2 levels in the bed nucleus of the stria terminalis. J Neurosci 2012, 32:6906-6916.
• [106]Belujon P, Grace AA: Hippocampus, amygdala, and stress: interacting systems that affect susceptibility to addiction. Ann NY Acad Sci 2011, 1216:114-121.
• [107]Martin-Fardon R, Ciccocioppo R, Aujla H, Weiss F: The dorsal subiculum mediates the acquisition of conditioned reinstatement of cocaine-seeking. Neuropsychopharmacology 2008, 33:1827-1834.
• [108]Sartor GC, Aston-Jones GS: A septal-hypothalamic pathway drives orexin neurons, which is necessary for conditioned cocaine preference. J Neurosci 2012, 32:4623-4631.
• [109]Mann JJ: Role of the serotonergic system in the pathogenesis of major depression and suicidal behavior. Neuropsychopharmacology 1999, 21:99S-105S.
• [110]Kirby LG, Zeeb FD, Winstanley CA: Contributions of serotonin in addiction vulnerability. Neuropharmacology 2011, 61:421-432.
• [111]Ryabinin AE, Yoneyama N, Tanchuck MA, Mark GP, Finn DA: Urocortin 1 microinjection into the mouse lateral septum regulates the acquisition and expression of alcohol consumption. Neuroscience 2008, 151:780-790.
• [112]Liu J, Yu B, Orozco-Cabal L, Grigoriadis DE, Rivier J, Vale WW, Shinnick-Gallagher P, Gallagher JP: Chronic cocaine administration switches corticotropin-releasing factor2 receptor-mediated depression to facilitation of glutamatergic transmission in the lateral septum. J Neurosci 2005, 25:577-583.
• [113]Henry B, Vale W, Markou A: The effect of lateral septum corticotropin-releasing factor receptor 2 activation on anxiety is modulated by stress. J Neurosci 2006, 26:9142-9152.
• [114]Bale TL, Vale WW: CRF and CRF receptors: role in stress responsivity and other behaviors. Annu Rev Pharmacol Toxicol 2004, 44:525-557.